FDA Inspection 1122803 — Piedmont Reproductive Endocrinology Group, Pa
The FDA completed an inspection of Piedmont Reproductive Endocrinology Group, Pa on January 28, 2020 in Greenville, SC. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- January 28, 2020
- Fiscal Year
- 2020
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Greenville, SC (United States)